Asset Acquisition, Consideration Transferred, Net

No definition available.

Name:	amag_AssetAcquisitionConsiderationTransferredNet
Namespace Prefix:	amag_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

- Definition

Asset Acquisition, Contingent Consideration Arrangements, Range Of Outcomes, Value, High

+ References

No definition available.

+ Details

Name:	amag_AssetAcquisitionContingentConsiderationArrangementsRangeOfOutcomesValueHigh
Namespace Prefix:	amag_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	instant

- Definition

Asset Acquisition, Contingent Consideration, Liability

+ References

No definition available.

+ Details

Name:	amag_AssetAcquisitionContingentConsiderationLiability
Namespace Prefix:	amag_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	instant

- Definition

Asset Acquisition, Contingent Consideration, Milestone Payment

+ References

No definition available.

+ Details

Name:	amag_AssetAcquisitionContingentConsiderationMilestonePayment
Namespace Prefix:	amag_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

- Definition

Asset Acquisition, Contingent Consideration Terms, Credited Percentage

+ References

No definition available.

+ Details

Name:	amag_AssetAcquisitionContingentConsiderationTermsCreditedPercentage
Namespace Prefix:	amag_
Data Type:	num:percentItemType
Balance Type:	na
Period Type:	instant

- Definition

Asset Acquisition, Contingent Consideration Terms, Royalty Percentage

+ References

No definition available.

+ Details

Name:	amag_AssetAcquisitionContingentConsiderationTermsRoyaltyPercentage
Namespace Prefix:	amag_
Data Type:	num:percentItemType
Balance Type:	na
Period Type:	duration

- Definition

Asset Acquisition, Potential Milestone Payment, Triggering Event, Threshold Amount

+ References

No definition available.

+ Details

Name:	amag_AssetAcquisitionPotentialMilestonePaymentTriggeringEventThresholdAmount
Namespace Prefix:	amag_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

- Definition

Asset Acquisition, Recognized Identifiable Assets Acquired And Liabilities Assumed, Indefinite-Lived Intangibles

+ References

No definition available.

+ Details

Name:	amag_AssetAcquisitionRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibles
Namespace Prefix:	amag_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	instant

- Definition

Asset Acquisition, Recognized Identifiable Assets Acquired And Liabilities Assumed, Intangibles

+ References

No definition available.

+ Details

Name:	amag_AssetAcquisitionRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles
Namespace Prefix:	amag_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	instant

- Definition

Option Agreement, Contingent Consideration, Liability

+ References

No definition available.

+ Details

Name:	amag_OptionAgreementContingentConsiderationLiability
Namespace Prefix:	amag_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	instant

- Definition

Option Agreement, Potential Sales Milestone Payment, Triggering Event, Threshold Amount

+ References

No definition available.

+ Details

Name:	amag_OptionAgreementPotentialSalesMilestonePaymentTriggeringEventThresholdAmount
Namespace Prefix:	amag_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

- Definition

Payments Related to Collaborative Arrangement

+ References

No definition available.

+ Details

Name:	amag_PaymentsRelatedToCollaborativeArrangement
Namespace Prefix:	amag_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

- Definition

Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.

+ References

No definition available.

+ Details

Name:	us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems
Namespace Prefix:	us-gaap_
Data Type:	xbrli:stringItemType
Balance Type:	na
Period Type:	duration

- Definition

The amount of impairment loss recognized in the period resulting from the write-down of the carrying amount of a finite-lived intangible asset to fair value.

+ References

Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 28
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=118932676&loc=d3e3602-108585

Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 350
-SubTopic 30
-Section 50
-Paragraph 3
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=66006027&loc=d3e16373-109275

+ Details

Name:	us-gaap_ImpairmentOfIntangibleAssetsFinitelived
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	duration

- Definition

Minimum amount of other commitment not otherwise specified in the taxonomy. Excludes commitments explicitly modeled in the taxonomy, including but not limited to, long-term and short-term purchase commitments, recorded and unrecorded purchase obligations, supply commitments, registration payment arrangements, leases, debt, product warranties, guarantees, environmental remediation obligations, and pensions.

+ References

No definition available.

+ Details

Name:	us-gaap_OtherCommitment
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	instant

- Definition

Number of shares of stock issued during the period as part of a transaction to acquire assets that do not qualify as a business combination.

+ References

No definition available.

+ Details

Name:	us-gaap_StockIssuedDuringPeriodSharesPurchaseOfAssets
Namespace Prefix:	us-gaap_
Data Type:	xbrli:sharesItemType
Balance Type:	na
Period Type:	duration

- Definition

Value of shares of stock issued during the period as part of a transaction to acquire assets that do not qualify as a business combination.

+ References

No definition available.

+ Details

Name:	us-gaap_StockIssuedDuringPeriodValuePurchaseOfAssets
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

- Details

Name:	srt_CounterpartyNameAxis=amag_VeloBioLLCMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_ContingentConsiderationByTypeAxis=amag_RegulatoryMilestoneAchievementMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_ContingentConsiderationByTypeAxis=amag_RegulatoryMilestoneAchievementU.S.FoodAndDrugAdministrationApprovalMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_ContingentConsiderationByTypeAxis=amag_AnnualSalesMilestoneAchievementsMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	srt_RangeAxis=srt_MinimumMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	srt_RangeAxis=srt_MaximumMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_ContingentConsiderationByTypeAxis=amag_CommercialMilestonePaymentsMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	srt_CounterpartyNameAxis=amag_EndoceuticsInc.Member
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	srt_CounterpartyNameAxis=amag_PalatinTechnologiesInc.Member
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	srt_ProductOrServiceAxis=amag_IntrarosaMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_DevelopedTechnologyRightsMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_ContingentConsiderationByTypeAxis=amag_SalesMilestonesAchievementMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_ContingentConsiderationByTypeAxis=amag_FirstSalesMilestoneAchievementMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_ContingentConsiderationByTypeAxis=amag_DeliveryOfIntrarosaLaunchQuantitiesMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_ContingentConsiderationByTypeAxis=amag_FirstAnniversaryOfClosingMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_ContingentConsiderationByTypeAxis=amag_TieredRoyaltiesMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	srt_ProductOrServiceAxis=amag_VyleesiProductsMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_ContingentConsiderationByTypeAxis=amag_RegulatoryMilestoneAchievementAcceptanceByU.S.FoodAndDrugAdministrationOfNewDrugApplicationMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_ContingentConsiderationByTypeAxis=amag_AchievementOfCertainAnnualSalesMilestonesOverCourseOfLicenseAgreementMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	amag_AssetAcquisitionAxis=amag_PerospherePharmaceuticalsInc.Member
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_ContingentConsiderationByTypeAxis=amag_MilestoneAchievementApprovalByEuropeanMedicinesAgencyMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

Acquisitions, Collaboration, License and Other Strategic Agreements (Details) - USD ($) $ in Millions			1 Months Ended					3 Months Ended			12 Months Ended
	Jan. 16, 2019	Apr. 03, 2017	Jun. 30, 2019	Sep. 30, 2018	Jun. 30, 2018	Feb. 28, 2017	Jan. 31, 2017	Dec. 31, 2019	Sep. 30, 2017	Jun. 30, 2017	Dec. 31, 2019	Dec. 31, 2018
Velo Bio, LLC \| Regulatory Milestone Achievement
Collaborative Agreements
Milestone payments				$ 5.0
Velo Bio, LLC \| Regulatory Milestone Achievement, U.S.Food And Drug Administration Approval
Collaborative Agreements
Milestone payments				30.0
Velo Bio, LLC \| Annual Sales Milestone Achievements
Collaborative Agreements
Milestone payments				240.0
Velo Bio, LLC \| Annual Sales Milestone Achievements \| Minimum
Collaborative Agreements
Sales milestone targets				300.0
Velo Bio, LLC \| Annual Sales Milestone Achievements \| Maximum
Collaborative Agreements
Sales milestone targets				900.0
Velo Bio, LLC \| Commercial Milestone Payments
Collaborative Agreements
Milestone payments				$ 10.0
Endoceutics, Inc.
Collaborative Agreements
Payments related to collaborative arrangement		$ 50.0
Number of shares issued under arrangement (in shares)		600,000
Net shares issued in connection with license agreement, value		$ 13.5
Consideration recorded										$ 83.5
IPR&D expense										5.8
Palatin Technologies, Inc.
Collaborative Agreements
Payments related to collaborative arrangement						$ 60.0
Out-of-pocket expenses (up to)						25.0
Intrarosa \| Endoceutics, Inc. \| Developed Technology Rights
Collaborative Agreements
Finite-lived intangible assets										$ 77.7
Impairment of intangible assets											$ 56.9
Intrarosa \| Endoceutics, Inc. \| Sales Milestones Achievement
Collaborative Agreements
Future contingent payments (up to)						895.0
Intrarosa \| Endoceutics, Inc. \| First Sales Milestone Achievement
Collaborative Agreements
Potential milestone payment, triggering event, sales						150.0
Future contingent payments (up to)						$ 15.0
Intrarosa \| Endoceutics, Inc. \| Delivery of Intrarosa Launch Quantities
Collaborative Agreements
Payments related to collaborative arrangement									$ 10.0
Intrarosa \| Endoceutics, Inc. \| First Anniversary of Closing
Collaborative Agreements
Payments related to collaborative arrangement												$ 10.0
Intrarosa \| Endoceutics, Inc. \| Tiered Royalties
Collaborative Agreements
Royalty percentage, maximum						25.00%
Vyleesi Products \| Palatin Technologies, Inc. \| Developed Technology Rights
Collaborative Agreements
Impairment of intangible assets								$ 39.0
Vyleesi Products \| Palatin Technologies, Inc. \| First Sales Milestone Achievement
Collaborative Agreements
Potential milestone payment, triggering event, sales							$ 250.0
Future contingent payments (up to)							25.0
Vyleesi Products \| Palatin Technologies, Inc. \| Regulatory Milestone Achievement, U.S.Food And Drug Administration Approval
Collaborative Agreements
Payments related to collaborative arrangement			$ 60.0
Vyleesi Products \| Palatin Technologies, Inc. \| Regulatory Milestone Achievement, Acceptance by U.S.Food and Drug Administration of New Drug Application
Collaborative Agreements
Payments related to collaborative arrangement					$ 20.0
Vyleesi Products \| Palatin Technologies, Inc. \| Achievement of Certain Annual Sales Milestones over Course of License Agreement
Collaborative Agreements
Future contingent payments (up to)							$ 300.0
Perosphere Pharmaceuticals Inc.
Collaborative Agreements
Contingent consideration (up to)	$ 365.0
Perosphere Pharmaceuticals Inc. \| Regulatory Milestone Achievement
Collaborative Agreements
Contingent consideration (up to)	$ 140.0
Credited percentage	50.00%
Perosphere Pharmaceuticals Inc. \| Milestone Achievement, Approval by European Medicines Agency
Collaborative Agreements
Contingent consideration (up to)	$ 40.0
Perosphere Pharmaceuticals Inc. \| Sales Milestones Achievement
Collaborative Agreements
Contingent consideration (up to)	225.0
Perosphere Pharmaceuticals Inc. \| First Sales Milestone Achievement
Collaborative Agreements
Contingent consideration, milestone payment	20.0
Potential milestone payment, triggering event, sales	$ 100.0